MeiraGTx reports Q3 2026 results, sets bota-vec filing timeline
MeiraGTx plans to submit an EU marketing application for bota-vec in December 2026 and a U.S. BLA in early 2027, with a Parkinson's disease Phase 3 study targeted to start in Q1 2027.
MeiraGTx Holdings plc reported financial and operational results for the quarter ended September 30, 2026, on November 12, 2026. For botaretigene sparoparvovec (bota-vec), its gene therapy for X-linked retinitis pigmentosa, the MAA dossier is complete and in publishing, with the company intending to submit it to the EMA in December 2026, pending EMA confirmation of the submission date.1 CEO Alexandria Forbes said the company has been preparing its market access and commercial teams ahead of an anticipated launch of bota-vec in late 2027.1
For AAV2-hAQP1 in radiation-induced xerostomia, the pivotal Phase 2 "AQUAx2" study completed enrollment in the second quarter of 2026. The company said the trial is on schedule for a 12-month data readout in the middle of 2027, which could support a BLA filing by the end of that year and possible U.S. approval in 2028.1
Hologen is described in the filing as MeiraGTx's JV partner that contributed AI-based analyses used in the RMAT application for AAV-GAD.1
On the riboswitch platform, the company has prioritized a Ribo-Leptin program followed by a neuropathic pain program for planned IND submissions.1 A single ascending dose/multiple ascending dose study of its lead small molecule is expected to begin in December 2026, with data to inform dosing for first-in-human combination studies in 2027.1
On financing, MeiraGTx held about $184.7 million in cash and equivalents as of September 30, 2026.1 Combined with a pending $95.0 million upfront payment from Hologen and related reimbursements, the company said it expects to fund operations into the second half of 2028.1 Net loss attributable to ordinary shareholders was $51.3 million for the quarter, compared with $50.5 million a year earlier.1
Fact check notes
- Sentence removed
That is expected to be followed by a full BLA submission to the FDA in the first quarter of 2027.
a corporate relationship the sources do not state - Sentence removed
On Parkinson's disease, a joint venture called Reogen Limited, formed with Hologen, intends to start a Phase 3 study of AAV-GAD in the first quarter of 2027.
a corporate relationship the sources do not state
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.